Sign In
Buy FMS
$20.90
+0.350 (+1.70%)
At Close: Jun 03, 2026
2 Dividend Aristocrat Bargains That Could Potentially Triple In 5 Years
01:00pm, Saturday, 11'th Jun 2022 Seeking Alpha
In the 2022 bear market, aristocrats are outperforming the S&P 500 by 2X and the Nasdaq by 3X, falling just 7% YTD.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
02:44pm, Tuesday, 10'th May 2022 Zacks Investment Research
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
My, Oh My, 10 Dividend Aristocrat Strong Buys
01:30pm, Tuesday, 10'th May 2022 Seeking Alpha
The markets are in turmoil, crashing at rates that have shocked even market veterans. This creates bargain-hunting opportunities. See 10 aristocrat buys here.
Fresenius Medical (FMS) Q1 Earnings & Revenues Top Estimates
12:03pm, Tuesday, 10'th May 2022
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
Fresenius Medical Care AG & Co. (FMS) CEO Rice Powell on Q1 2022 Results - Earnings Call Transcript
12:33pm, Wednesday, 04'th May 2022
Fresenius Medical Care AG & Co. (NYSE:FMS ) Q1 2022 Earnings Conference Call May 4, 2022 9:30 AM ET Company Participants Dominik Heger - Head of IR Rice Powell - CEO Helen Giza - CFO Conference Call P
Fresenius: The Upside Is Getting Bigger
08:07am, Monday, 02'nd May 2022
Fresenius is an interesting investment - certainly in part because it doesn't require an ADR, you can invest in the medical care wing with the symbol FMS. The company's organic growth has been slowed
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
01:33pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
Fresenius Medical (FMS) Launches Campaign to Boost Kidney Care
11:18am, Thursday, 14'th Apr 2022
Fresenius Medical's (FMS) My Reason campaign will help scientists understand genetic variations in patients with chronic kidney disease in a better way.
My Dividend Stock Portfolio: March 2022 Update - 101 Holdings And 29 Buys
05:30am, Thursday, 07'th Apr 2022 Seeking Alpha
The war in Ukraine continues to dominate market movements. Read why I am not selling and predominantly focusing on adding dividend income via select purchases.
2 TeleHealth Stocks to Buy, 1 to Watch in 2022
03:23pm, Saturday, 02'nd Apr 2022 The Motley Fool
Patient care via phone and video is far from finished.
Fresenius Medical's (FMS) Merger Deal to Improve Kidney Care
02:04pm, Wednesday, 23'rd Mar 2022 Zacks Investment Research
Fresenius Medical's (FMS) merger deal to build an independent entity to transform kidney care and health equity throughout the United States.
Here’s Why Fresenius Medical Care (FMS) Landed in Artisan Partners’ Detractor List
05:20am, Tuesday, 01'st Mar 2022 Insider Monkey
Artisan Partners, a high value-added investment management firm, published its “Artisan Value Fund” fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Is it Still Worthy to Keep Your Fresenius Medical Care (FMS) Shares?
05:15am, Thursday, 24'th Feb 2022 Insider Monkey
Artisan Partners, a high value-added investment management firm, published its ‘Artisan International Value Fund’ fourth quarter 2021 investor letter – a copy of which can be downloaded here.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
04:10pm, Wednesday, 23'rd Feb 2022 Zacks Investment Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
12:20pm, Wednesday, 23'rd Feb 2022
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong performance across all the geographic regions and segments.
